Vor Biopharma terminates at-the-market sales agreement with Jefferies LLC

Vor Biopharma Inc.

Notice of termination given December 9, 2022; effective December 22, 2022.
Sales agreement allowed at-the-market offerings of common stock through Jefferies.
Through termination, 856,030 shares sold for net proceeds of $4.3 million.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vor Biopharma Inc. terminated Sales Agreement with Jefferies LLC (effective 2022-12-22).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Effective: 2022-12-22

Exact text from the filing

On December 9, 2022, Vor Biopharma Inc. (the “ Company ”) notified Jefferies LLC (“ Jefferies ”) of its decision to terminate the Open Market Sale Agreement SM , dated as of March 14, 2022, (the “ Sales Agreement ”) between the Company and Jefferies, effective as of December 22, 2022 (the “ Termination Date ”).

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-304849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.